Safety of ezetimibe in lipid-lowering treatment: systematic review and meta-analysis of randomised controlled trials and cohort studies

Yang Wang, Shipeng Zhan, Heyue Du, Jing Li, Safi U Khan, Bert Aertgeerts, Gordon Guyatt, Qiukui Hao, Geertruida Bekkering, Ling Li, Nicolas Delvaux, Na Su, Irbaz Riaz, Per Olav Vandvik, Haoming Tian, Sheyu Li

ABSTRACT

OBJECTIVE To determine the harms of ezetimibe in people who need lipid-lowering treatment.

DESIGN Systematic review and meta-analysis.

DATA SOURCES Randomised controlled trials and cohort studies.

ELIGIBILITY CRITERIA FOR SELECTING STUDIES Studies comparing ezetimibe with placebo, standard care, or other lipid-lowering agents in people who need lipid-lowering treatment with a follow-up duration of at least six months (or 24 weeks). The relative effects for potential harms of ezetimibe were pooled by use of random effect pairwise meta-analyses for randomised controlled trials and the evidence from observational studies was narratively summarised. The certainty of evidence was assessed using the Grading of Recommendation Assessment, Development, and Evaluation.

RESULTS 48 randomised controlled trials with 28,444 participants (median follow-up 34 weeks, range 24-312 weeks) and four observational studies with 1667 participants (median follow-up 282 weeks, range 72-400 weeks) were included. The meta-analyses of randomised trials showed moderate to high certainty that ezetimibe was not associated with cancer (relative risk 1.01; 95% confidence interval 0.92 to 1.11), fractures (0.90; 0.74 to 1.10), discontinuation due to any adverse event (0.87; 0.74 to 1.03), gastrointestinal adverse events leading to discontinuation (1.34; 0.58 to 3.08), myalgia or muscular pain leading to discontinuation (0.82; 0.51 to 1.33), neurocognitive events (1.48; 0.58 to 3.81), or new-onset diabetes (0.88; 0.61 to 1.28). The narrative analysis of observational studies provided consistent findings. No credible subgroup effects were identified for the harm outcomes, including shorter versus longer follow-up duration of trials.

CONCLUSIONS Ezetimibe results in little to no difference in adverse events or other undesirable effects compared with placebo, usual care or other lipid-lowering agents.

WHAT IS AREADLY KNOWN ON THIS TOPIC

⇒ Ezetimibe lowers low density lipoprotein cholesterol and reduces cardiovascular risks by blocking the gastrointestinal absorption of dietary cholesterol

⇒ Although ezetimibe is generally safe, there are concerns about its potential harms including cancer, neurocognitive events, fractures, gastrointestinal adverse events, myalgia, muscular pain, and new-onset diabetes

WHAT THIS STUDY ADDS

⇒ Adding ezetimibe results in little to no difference in adverse events or other undesirable effects in people who need lipid-lowering treatment

HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE, OR POLICY

⇒ When deciding to add ezetimibe to statins for lipid-lowering treatment, clinicians can have confidence in the evidence that adverse events are rare

Introduction

Cardiovascular disease is one of the leading causes of death and disability worldwide.1-3 Statins are first line cholesterol-lowering drugs for the reduction of cardiovascular risk but can cause adverse effects such as myalgia, muscular pain, and new-onset diabetes.4-5 Ezetimibe, an oral cholesterol-lowering drug taken after statins, which inhibits intestinal cholesterol absorption and decreases biliary cholesterol secretion, lowers low density lipoprotein cholesterol (LDL-C) by 20%.6-9 Clinical trials and systematic reviews have established that ezetimibe can reduce cardiovascular events.10-13 Guidelines from the European Society of Cardiology14 and American Heart Association15 recommend ezetimibe as a second lipid-lowering drug in addition to treatment with statins when LDL-C treatment goals are not met, or as a single drug in case of statin-intolerance. The number of prescriptions of ezetimibe doubled in North America from 2003 to 2006 for the primary and secondary prevention of cardiovascular diseases.16

Although ezetimibe is well tolerated in clinical practice, some studies suggest concerns regarding potential harms such as cancer, neurocognitive events, fractures, gastrointestinal adverse events, myalgia, muscular pain, and new-onset diabetes.4-17-22 The cause and magnitude of adverse events or undesirable effects of ezetimibe remain unclear. Therefore, we conducted a pairwise systematic review and meta-analysis of randomised controlled trials and observational studies to evaluate the safety of ezetimibe in people who need lipid-lowering treatment. This systematic review quantitatively informed the potential harms of ezetimibe for a
parallel clinical practice guideline with risk-stratified recommendations for ezetimibe and PCSK9 inhibitors. This guideline forms part of a BMJ Rapid Recommendation and is a collaborative effort by the MAGIC Evidence Ecosystem Foundation (https://magicevidence.org) and The BMJ (box 1). For the visual abstract of this paper, see figure 1.

Methods

Study design
This systematic review was reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (known as PRISMA) statement and the Meta-analysis of Observational Studies in Epidemiology (known as MOOSE) statement (checklists in online supplemental tables S1 and S2). We registered the protocol in PROSPERO (CRD42020187437).

Guideline panel and patient involvement
The BMJ Rapid Recommendation panel, including clinicians, methodologists, and patients provided critical oversight over the steps of this review. The panel included cardiologists, general practitioners, general internists, endocrinologists, a geriatrician, methodologists, and three patient partners. Patient partners received personal training and individual support in the methods used throughout the guideline development process. The panel assisted in framing the study question, defining the interventions and comparisons, prioritising outcome measures, and proposing subgroup analyses. Three patient partners were members of the guideline panel that contributed to this systematic review and the associated BMJ Rapid Recommendation.

Data sources
We searched Medline, EMBASE, and Cochrane Central Register of Controlled Trials (CENTRAL) from inception to July 2021. We also searched ClinicalTrials.gov for completed unpublished registered trials with results. The search strategy is shown in online supplemental tables S3 and S4.

Paired reviewers (YW and HD) searched the literature and selected studies through screening titles and abstracts. Potentially eligible papers

Figure 1 | Visual abstract

---

**BOX 1 | LINKED ARTICLES IN THIS BMJ RAPID RECOMMENDATIONS CLUSTER**


⇒ Summary of the results from the Rapid Recommendation process


⇒ Review and network meta-analysis of all available randomised trials that assessed effects of PCSK9 inhibitors and ezetimibe with or without statin therapy for cardiovascular risk reduction

⇒ Harm reviews


⇒ MAGICApp (https://app.magicapp.org)

⇒ Expanded version of results with multi-layered recommendations, evidence summaries, and decision aids for use on all devices

---

**Figure 1 | Visual abstract**

---

Wang Y, et al. BMJMED 2022;0. doi:10.1136/bmjmed-2022-000134
were screened in full text. In case of conflict, a third reviewer (SL) arbitrated disagreement by discussion. We crosschecked the study inclusion with a previously published systematic review.13

We included randomised controlled trials and cohort studies that compared ezetimibe with placebo, standard care, or other lipid-lowering agents with at least six months (or 24 weeks) follow-up duration. We included studies explicitly reporting data for at least one outcome of interest, including cancer (any type), new-onset diabetes mellitus, neurocognitive events, fractures, myalgia or muscular pain leading to discontinuation, discontinuation due to gastrointestinal adverse events, or discontinuation due to any adverse effect. The longest follow-up duration or the largest population study was included when studies reported on the same or overlapping populations. Only studies published in English were included.

Data were collected in a predefined collection form incorporating study characteristics (eg, first author name, year of publication, study design, sample size, follow-up duration, prevention type, the intervention of control, and background treatment); baseline characteristics (eg, age, sex, body mass index, LDL-C, high density lipoprotein cholesterol, and triglycerides); intervention characteristics (eg, drug dose, treatment duration); and safety outcomes (eg, number of events and patients of each outcome) for randomised controlled trials. If a published trial did not report the outcome information, while the corresponding ClinicalTrials.gov reported relevant data, we collected data from the registry report. When the data in publication and ClinicalTrials.gov conflicted, we used the data from the publication. For observational studies, additional data were collected, including prospective or retrospective design, exposure, data source, and methods for comparability (that is, matching or adjusting for confounding variables). Adjusted effect estimates (that is, relative risks or odds ratios) and corresponding 95% confidence intervals were preferred to raw data of adverse events or odds ratios) and corresponding 95% confidence intervals were preferred to raw data of adverse events.

adjusted effect estimates (that is, relative risks or or odds ratios) and corresponding 95% confidence intervals were preferred to raw data of adverse events.

Statistical analysis

For the included randomised controlled trials, we pooled relative risks and their 95% confidence intervals using the random effects model for all meta-analyses. Statistical heterogeneity was assessed by $\chi^2$ and $I^2$ tests with significance defined by $\chi^2$ $P<0.1$ or $I^2>50%$. We used baseline risks for each outcome based on the pooled event rates of included control groups and calculated absolute effects for each outcome at both five years and two years. As a result of limited data reported and low certainty of evidence, we did not pool outcome data quantitatively in the analysis of observational studies but instead conducted a narrative summary of the included studies.

We analysed three subgroup analyses to explore the potentially hypothetical heterogeneity. Firstly, the follow-up duration (<48 v ≥48 weeks) in particular, potential affects of larger relative effects in studies with longer follow-up duration. Secondly, risk of bias (low v high risk), focusing on larger relative effects in studies with high risk. Results from high risk items from the Cochrane Collaboration Risk of Bias Tool are noted. Finally, type of control (placebo or usual care v active agents) with larger relative effects in studies with placebo or usual care.

As recommended by reviewers, we exploratorily performed a meta-regression according to different baseline LDL-C concentrations. When the included number of non-zero-event trials surpassed 10, funnel plots, Begg’s rank correlations, and Egger’s linear regression were applied in evaluating publication bias. We used the fixed effects model to pool the data for each outcome as the sensitivity analysis. All data analyses were done using RStudio (R Pack Version 3.6.1).

To evaluate the certainty of evidence, we used the Grading of Recommendation Assessment, Development, and Evaluation (known as GRADE) framework29 and assessed the credibility of subgroup analyses based on the literature.30

Patient and public involvement

Three patient partners were involved in the design of this research.

Results

Included studies

Of 6881 citations of randomised controlled trials, we included 48 with a total of 28444 participants (figure 2, table 1, and online supplemental tables S6 and S7).11 Follow-up durations ranged from 24 to 312 weeks (median 34 weeks). The mean age of participants was 62.6 years, 71.9% were male, the mean baseline LDL-C was 112.1 mg/dL (2.9 mmol/L), and the mean proportion of individuals using statins at admission was 39.6% (table 1). Of 25 multicentre trials, treatment regimens included ezetimibe in monotherapy (663 participants in 11 trials), ezetimibe plus statin (13230 participants in 36 trials), and ezetimibe plus fibrate (340 participants in one trial).

Of 3625 citations of observational studies, we included four cohort retrospective cohorts with 1667 participants in our narrative summary (figure 2, table 2, and online supplemental table S10).31–34
Follow-up durations ranged from 72 to 400 weeks (that is, 1.38-7.70 years; median 282 weeks (that is, 5.42 years)). The population from two studies were identified from electronic health records. The mean age of the participants was 59.5 years, 35.6% were male, the mean baseline LDL-C was 191.0 mg/dL (4.9 mmol/L), and 9.7% of participants were using statins at admission. Three studies compared ezetimibe plus statin versus statin alone, and one other compared ezetimibe versus colesevelam.

Risk of bias
We rated the overall risk of bias as low across all 48 included trials; 29 trials raised concerns (online supplemental file 1). We rated 14 (29%) studies as high risk of bias because the number of missing participants was higher than 20% or the analysis was not done by an intention-to-treat protocol. We rated 18 (38%) trials as high risk of bias owing to inadequate masking of participants and personnel, 14 (29%) trials owing to an open label design, and four (8%) trials because the trial design did not have a matching placebo. The overall scores of the Newcastle-Ottawa quality assessment scale were six to seven among the included observational studies, indicating some risks of bias (table 3; online supplemental table S11).

Meta-analyses of randomised controlled trials
As shown in figure 3, moderate to high certainty evidence indicated that ezetimibe has little to no effect on the risks of cancer (relative risk 1.01; 95% confidence interval 0.92 to 1.11), fractures (0.90; 0.74 to 1.10), discontinuation due to any adverse events (0.87; 0.74 to 1.03), discontinuation due to gastrointestinal adverse events (1.34; 0.58 to 3.08), myalgia or muscular pain leading to discontinuation (0.82; 0.51 to 1.33), neurocognitive events (1.48; 0.58 to 3.81), or new-onset diabetes (0.88; 0.61 to 1.28). We downgraded the certainty of the evidence to moderate for discontinuation due to any adverse events for indirectness because of the composite nature of the outcome. We also
downgraded the certainty of evidence of discontinuation due to any gastrointestinal adverse events and neurodegenerative events for imprecision because of wide 95% confidence intervals, which could not support clinical decision making.

Subgroups and sensitivity analysis
None of the subgroup analyses identified potential subgroup effects in different trials with different follow-up durations, risk of bias, and type of control (online supplemental table S8 and figures S3–S5). For example, the cancer risk did not show heterogeneity across the subgroups of <48 weeks follow-up (relative risk 0.79; 95% confidence interval 0.21 to 3.01) and ≥48 weeks follow-up (1.01; 0.92 to 1.11) with the interaction P value being 0.72. The meta-regression did not identify any association between baseline LDL-C concentrations and outcomes (online supplemental table S13).

The sensitivity analyses supported the robustness of the pooled results using the fixed effects model (online supplemental figures S7–S19). Neither funnel plots nor Begg’s and Egger’s tests for the outcomes of cancer and discontinuation due to any adverse events did not identify signals of publication bias (online supplemental table S9).

Table 1 | Baseline characteristics of included trials

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>No (%)</th>
<th>Interquartile range</th>
<th>Range</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Eligible studies:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total No of trials</td>
<td>48</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Median trial size</td>
<td>131</td>
<td>65-246</td>
<td>18-18144</td>
</tr>
<tr>
<td>Median follow-up (weeks)</td>
<td>34</td>
<td>24-32</td>
<td>24-312</td>
</tr>
<tr>
<td>No of studies funded by pharmaceutical companies</td>
<td>26 (54.2)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>No of studies that were phase 2/3</td>
<td>12 (25.0)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>No of studies that were not phase 2/3</td>
<td>36 (75.0)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Participants:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean age (years)</td>
<td>62.6</td>
<td>57.7-64.0</td>
<td>45.9-84.1</td>
</tr>
<tr>
<td>Male sex (%)</td>
<td>71.9</td>
<td>51.9-75.3</td>
<td>27.6-89.7</td>
</tr>
<tr>
<td>Mean LDL-C (mg/dL) at baseline</td>
<td>112.1</td>
<td>109.92-150.47</td>
<td>82.05-318.40</td>
</tr>
<tr>
<td>Mean proportion (% of patients receiving statin at baseline)</td>
<td>39.6</td>
<td>0-100</td>
<td>0-100</td>
</tr>
<tr>
<td><strong>Region:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>World</td>
<td>12 (25.0)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Europe*</td>
<td>9 (18.8)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Asia†</td>
<td>20 (41.7)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>America</td>
<td>7 (14.6)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td><strong>Prevention type:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary prevention</td>
<td>12 (25.0)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Secondary prevention</td>
<td>24 (50.0)</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>Unspecific prevention</td>
<td>12 (25.0)</td>
<td>—</td>
<td>—</td>
</tr>
</tbody>
</table>

LDL-C=low density lipoprotein cholesterol (1 mg/dL=0.0259 mmol/L).
*One study conducted in Russia was included in this category.
†One study conducted in Turkey was included in this category.

Table 2 | Characteristics of the included observational studies

<table>
<thead>
<tr>
<th>Study</th>
<th>Study design</th>
<th>Data sources</th>
<th>Funding</th>
<th>Location</th>
<th>No of centres</th>
<th>No of participants</th>
<th>Median follow-up duration</th>
<th>Mean LDL-C (mg/dL) at baseline</th>
<th>Prevention type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Barkas et al31</td>
<td>Retrospective cohort study</td>
<td>NR</td>
<td>Not funded</td>
<td>Greece</td>
<td>796</td>
<td>6.84 years*</td>
<td>177.8</td>
<td></td>
<td>Primary</td>
</tr>
<tr>
<td>Kim et al32</td>
<td>Retrospective cohort study</td>
<td>Electronic medical records</td>
<td>Ministry of Health and Welfare, Republic of Korea</td>
<td>Single centre</td>
<td>665</td>
<td>4 years</td>
<td>NR</td>
<td>NR</td>
<td></td>
</tr>
<tr>
<td>Klosiewicz-Łatoszek et al33</td>
<td>Retrospective cohort study</td>
<td>NR</td>
<td>Sanofi</td>
<td>Poland</td>
<td>190</td>
<td>7.70 years†</td>
<td>239.8</td>
<td></td>
<td>Primary†</td>
</tr>
<tr>
<td>Rivers et al34</td>
<td>Retrospective cohort study</td>
<td>Electronic medical records</td>
<td>Sankyo Pharma</td>
<td>Single centre</td>
<td>16</td>
<td>Phase 1: 305 days, phase 2: 199 days</td>
<td>166</td>
<td></td>
<td>NR</td>
</tr>
</tbody>
</table>

LDL-C=low density lipoprotein cholesterol (1 mg/dL=0.0259 mmol/L); NR=not reported.
*Mean was estimated from median and interquartile range.
†Data in specific subpopulation of interest were not available, so data in overall population were presented.
Table 3 | Treatments, outcomes, and risk of bias of included observational studies

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Study</th>
<th>Treatment of interest</th>
<th>Control group</th>
<th>Summary of findings</th>
<th>NOS score (0-10)</th>
</tr>
</thead>
<tbody>
<tr>
<td>New-onset diabetes</td>
<td>Barkas et al&lt;sup&gt;31&lt;/sup&gt;</td>
<td>Ezetimibe+statin</td>
<td>Statin</td>
<td>Ezetimibe did not increase the risk of new-onset diabetes (adjusted OR 1.01; 95% CI 0.51 to 1.99). OR was adjusted for the log-transformed baseline fasting glucose levels and follow-up duration, the presence of metabolic syndrome, and family history of diabetes.</td>
<td>7</td>
</tr>
<tr>
<td></td>
<td>Kim et al&lt;sup&gt;32&lt;/sup&gt;</td>
<td>Simvastatin (20 mg) with ezetimibe (10 or 20 mg) complex</td>
<td>Simvastatin (20 and 40 mg)</td>
<td>Ezetimibe did not increase the risk of new-onset diabetes (adjusted OR via indirect comparison* 1.24; 95% CI 0.65 to 2.39). OR was adjusted for baseline variables, which were not reported explicitly.</td>
<td>7</td>
</tr>
<tr>
<td>Myalgia or muscular pain leading to discontinuation</td>
<td>Kłosiewicz-Latoszek et al&lt;sup&gt;33&lt;/sup&gt;</td>
<td>Ezetimibe+statin</td>
<td>Statin</td>
<td>No case of myalgia or muscular pain leading to discontinuation was reported in each group.</td>
<td>6</td>
</tr>
<tr>
<td>Discontinuation due to any gastrointestinal adverse events</td>
<td>Rivers et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Phase 1: ezetimibe; phase 2: ezetimibe+colesevelam</td>
<td>Phase 1: colesevelam; phase 2: ezetimibe+colesevelam</td>
<td>No case of discontinuation due to any gastrointestinal adverse events was reported in each group.</td>
<td>6</td>
</tr>
<tr>
<td>Discontinuation due to any adverse events</td>
<td>Rivers et al&lt;sup&gt;34&lt;/sup&gt;</td>
<td>Phase 1: ezetimibe; phase 2: ezetimibe+colesevelam</td>
<td>Phase 1: colesevelam; phase 2: ezetimibe+colesevelam</td>
<td>No case of discontinuation due to any adverse events was reported in each group.</td>
<td>6</td>
</tr>
</tbody>
</table>

CI=confidence interval; NOS=Newcastle-Ottawa quality assessment scale; OR=odds ratio.

*The comparison was indirect because the OR and 95% CI of simvastatin and ezetimibe versus imvastatin were calculated from the ORs and 95% CIs of simvastatin versus atorvastatin and of ezetimibe versus atorvastatin.

NARRATIVE SUMMARY OF OBSERVATIONAL STUDIES

Two retrospective studies<sup>31, 32</sup> suggested that ezetimibe was not associated with an increased risk of new-onset diabetes (adjusted odds ratio 1.01, 95% confidence interval 0.51 to 1.99; adjusted odds ratio via indirect comparison 1.24, 0.65 to 2.39) during the four to six year follow-up duration (table 3). Two studies reported no instances of myalgia or muscular pain during the follow-up duration.<sup>33, 34</sup> One study with 16 participants reported no cases of discontinuation due to any adverse events including gastrointestinal effects in a 10-month follow-up duration.<sup>35</sup> We consider these findings to be very low certainty evidence due to high risk of bias (new-onset diabetes, myalgia or muscular pain leading to discontinuation, discontinuation due to any gastrointestinal adverse events and discontinuation due to any adverse events), indirectness (new-onset diabetes and discontinuation due to any adverse events) and imprecision (myalgia or muscular pain leading to discontinuation, discontinuation due to any gastrointestinal adverse events and discontinuation due to any adverse events).

**Discussion**

**Main findings**

Moderate to high certainty evidence shows that ezetimibe has little to no effect on adverse events (compared with no ezetimibe), including cancer, new-onset diabetes, neurocognitive events, fractures, myalgia or muscular pain leading to discontinuation, or discontinuation due to gastrointestinal adverse events or any adverse events.

Drugs that do not cause adverse events are rare in clinical practice.<sup>35</sup> Unlike the pleiotropy of targets for other lipid-lowering drugs, ezetimibe lowers LDL-C concentration by blocking the Niemann-Pick C1 Like 1 (NPC1L1) protein, which inhibits intestinal cholesterol absorption, thus mimicking a low cholesterol diet.<sup>36, 37</sup> Ezetimibe does not directly interact with the lipid metabolism in the liver and other organs and is biologically safe, except for the potential harms of very low cholesterol intake, which remains open to debate.<sup>38</sup>

**Comparison with the previous studies**

We identified six previous meta-analyses investigating the safety concerns of ezetimibe.<sup>39-44</sup> Results for these studies were consistent with our findings, except that Zhao and colleagues<sup>44</sup> significantly linked ezetimibe to increased neurocognitive events in their network meta-analysis (network odds ratio 3.94, 95% confidence interval 1.18 to 13.12).

Neurocognitive safety is one of the most important concerns followed by very low LDL-C concentrations.<sup>45</sup> Nevertheless, the findings from our meta-analysis of randomised controlled trials did not show an effect of neurodegenerative events in people treated with ezetimibe, nor did the findings from the observational studies. Our study did not show an effect on cancer, a concern that was raised by the SEAS trial.<sup>22</sup> We did not note an association with fractures or gastrointestinal effects, events that could be linked to the limited absorption of lipids in intestines.<sup>5, 20, 21</sup> However, discontinuation due to any gastrointestinal adverse events and neurodegenerative events were downgraded to moderate certainty due to wide 95% confidence intervals. New evidence could change our confidence in these effects.<sup>46-47</sup>

Wang Y, et al. BMJMED 2022;0. doi:10.1136/bmjmed-2022-000134
<table>
<thead>
<tr>
<th>Outcomes</th>
<th>No of participants (studies)</th>
<th>Risk ratio (95% CI)</th>
<th>Risk ratio (95% CI)</th>
<th>Time frame</th>
<th>Baseline risk</th>
<th>Absolute risk change</th>
<th>Certainty rating</th>
<th>Certainty of evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any cancer</td>
<td>22 363 (10)</td>
<td>1.01 (0.92 to 1.11)</td>
<td>1.01 (0.92 to 1.11)</td>
<td>2 year</td>
<td>91</td>
<td>1 more per 1000 (7 fewer to 10 more)</td>
<td>□□□□□</td>
<td>High</td>
</tr>
<tr>
<td>Any fracture</td>
<td>20 291 (8)</td>
<td>0.90 (0.74 to 1.10)</td>
<td>0.90 (0.74 to 1.10)</td>
<td>2 year</td>
<td>30</td>
<td>3 fewer per 1000 (8 fewer to 3 more)</td>
<td>□□□□□</td>
<td>High</td>
</tr>
<tr>
<td>Discontinuation due to any adverse event</td>
<td>27 326 (40)</td>
<td>0.87 (0.74 to 1.03)</td>
<td>0.87 (0.74 to 1.03)</td>
<td>2 year</td>
<td>200</td>
<td>25 fewer per 1000 (51 fewer to 5 more)</td>
<td>□□□□□□</td>
<td>Moderate</td>
</tr>
<tr>
<td>Discontinuation due to any gastrointestinal adverse event</td>
<td>2432 (20)</td>
<td>1.34 (0.58 to 3.08)</td>
<td>1.34 (0.58 to 3.08)</td>
<td>2 year</td>
<td>22</td>
<td>8 more per 1000 (9 fewer to 47 more)</td>
<td>□□□□□□</td>
<td>Moderate</td>
</tr>
<tr>
<td>Myalgia or muscular pain leading to discontinuation</td>
<td>2438 (25)</td>
<td>0.82 (0.51 to 1.33)</td>
<td>0.82 (0.51 to 1.33)</td>
<td>2 year</td>
<td>70</td>
<td>13 fewer per 1000 (35 fewer to 23 more)</td>
<td>□□□□□</td>
<td>High</td>
</tr>
<tr>
<td>Neurocognitive events</td>
<td>19 887 (5)</td>
<td>1.48 (0.58 to 3.81)</td>
<td>1.48 (0.58 to 3.81)</td>
<td>2 year</td>
<td>1</td>
<td>0 more per 1000 (0 fewer to 3 more)</td>
<td>□□□□□□</td>
<td>Moderate</td>
</tr>
<tr>
<td>New-onset diabetes</td>
<td>20 319 (8)</td>
<td>0.88 (0.61 to 1.28)</td>
<td>0.88 (0.61 to 1.28)</td>
<td>2 year</td>
<td>9</td>
<td>1 fewer per 1000 (4 fewer to 7 more)</td>
<td>□□□□□</td>
<td>High</td>
</tr>
</tbody>
</table>

Figure 3 | Summary of findings for relative and absolute risks of the safety outcomes of ezetimibe. Hollow squares in the certainty rating column represent six rating domains listed in order from left to right including risk of bias, inconsistency, indirectness, imprecision, publication bias, and other concerns. Black squares means that the certainty was downgraded because of that domain. CI=confidence interval.
Strengths and limitations
Our study systematically reviewed all ezetimibe trials and cohort studies from literature and ClinicalTrials.gov and engaged a multidisciplinary panel to contextualize our findings into clinical practice. The GRADE approach based on the absolute effects facilitates the application in clinical practice. In trials, we did not identify credible subgroup effects for any of the harm outcomes regarding different follow-up durations. With the support from observational studies with a median follow-up duration of up to 7.7 years, our study supports the long term safety of the drug. Nevertheless, long term surveillance remains necessary.

The key limitation of this study is that the number of some events (that is, gastrointestinal and neurocognitive events) is rare and therefore findings for these events could be imprecise. Unfortunately, the included observational studies to supplement the trial evidence overall provided very low certainty evidence and were not powered to improve precision for these or other harm outcomes. A large scale, population based study could be helpful in the future. However, such rare events might not alter clinical decision making because of the very low absolute baseline risk. The systematic review did not provide direct evidence for people with characteristics that were not represented by the study population (e.g., low LDL-C concentration before treatment). People who might not be represented, therefore, should use when considering the direct evidence.

Conclusion
In this systematic review, moderate to high certainty evidence show that treatment with ezetimibe has some benefits (that is, cardiovascular and neurocognitive events) is rare and therefore findings for these events could be imprecise. Unfortunately, the included observational studies to supplement the trial evidence overall provided very low certainty evidence and were not powered to improve precision for these or other harm outcomes. A large scale, population based study could be helpful in the future. However, such rare events might not alter clinical decision making because of the very low absolute baseline risk. The systematic review did not provide direct evidence for people with characteristics that were not represented by the study population (e.g., low LDL-C concentration before treatment). People who might not be represented, therefore, should use when considering the direct evidence.

AUTHOR AFFILIATIONS
1Department of Endocrinology and Metabolism, Chinese Evidence-based Medicine Centre, Cochrane China Centre, and MAGIC China Centre, West China Hospital, Sichuan University, Chengdu, China
2Department of Pharmacy, Southwest Hospital, Army Medical University, Chongqing, China
3Department of Nephrology, West China Hospital, Sichuan University, Chengdu, China
4Department of Cardiology, Houston Methodist DeBakey Heart & Vascular Center, Houston, TX, USA
5Department of Public Health and Primary Care, Leuven, Leuven, Belgium
6Department of Clinical Epidemiology and Biostatistics, and Department of Medicine, McMaster University, Hamilton, ON, Canada
7Centre of Gerontology and Geriatrics/National Clinical Research Centre for Geriatrics, West China Hospital, Sichuan University, Chengdu, China
8School of Rehabilitation Science, McMaster University, Hamilton, Ontario, Canada
9Department of Pharmacy, West China Hospital, Sichuan University, Chengdu, China
10Mayo Clinic, Rochester, MN, USA
11Department of Medicine, Norwegian Institute of Public Health, Oslo, Norway
12Department of Medicine, Inlandet Hospital Trust, Gjøvik, Norway

Contributors
SL, HT, POV, IR, ND, GB, GG, BA, QH, and SUK conceived the study, YW performed the literature search; YW and JL screened studies for eligibility, YW, SL, LL, and SL assessed the risk of bias; YW and JL performed data extraction; SL, BA, GG, POV, and NS interpreted the data analysis; SL, BA, GG, QH, ND, and HD assessed the certainty of the evidence; HD wrote the draft of the manuscript; and all other authors revised the manuscript. SL is the guarantor. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted.

Funding
This work was funded by 1:3:5 project for disciplines of excellence–Clinical Research Incubation Project, West China Hospital, Sichuan University (Nos. 19HXFH011, ZYGD18022 and 2020XFe010). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from West China Hospital, Sichuan University for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Ethics approval
Not applicable.

Provenance and peer review
Not commissioned; externally peer reviewed.

Data availability statement
All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material
This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access
This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and licence their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

ORCID iD
Sheyu Li http://orcid.org/0000-0003-0060-0287

REFERENCES
et al. BMJ Med 2022;0. doi:10.1136/bmjmed-2022-000134

9


30 Sun X, Briel M, Busse JW, et al. Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10.1136/bmj-2022-000134).